Pamela Munster, MD

Kantonsschule Sargans, Switzerland, Baccalaureate, 1983, Sciences, Liberal Arts
University of Bern Switzerland, Doctorate, 1990, Medicine
University of Bern Switzerland, MD Thesis, 1992, Medicine

• 1990-1992
  University of Bern, Department of Physiology, Teaching Assignment in Physiology
• 1992-1993
  Indiana University at Indianapolis, Krannert Institute of Cardiology
• 1993-1996
  Residency in Internal Medicine Indiana University Medical Center at Indianapolis
• 1996-1999
  Hematology-Oncology Fellowship at Memorial Sloan Kettering Cancer Center/The New York Hospital-Cornell Medical Center New York
• 1999-2000
  Research Associate, Department of Medicine, Breast Program, Memorial Sloan Kettering Cancer Center, New York
• 2000-2001
  Clinical Assistant Member, Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Service
• 2001-2006
  Assistant Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
• 2006-2008
  Associate Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
• 2007-present
  Faculty Affiliate, Colorade State University, Ft. Collins, CO
• 2008-2010
  Associate Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF
• 2008-present
  Director, Early Phase Clinical Trials Program and Associate Director, Investigational Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center
• 2010-present
  Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF

• 1998
  John Mendelsohn House staff Teaching Award
• 1999
  AACR-AFLAC Young Investigators Scholar Award 1999
• 2000, 2001
  Byrne Fund Award
• 2003-2005
  Don Shula Career Development Award, 2003-2005
• 2007-2008
  Greatest Number of Investigator-Initiated Trials Written & Implemented, H. Lee Moffitt Cancer Center & Research Institute
• 2008
  Research Highlights, Department of Defense, Congressionally Directed Medical Research Programs

• Munster PN, Weingart R. Modulation of Cardiac Gap Junctions by Phorbol Esters. Experientia (1991) 47, 19.
• Munster PN, Weingart R. Effects of Phorbol esters on Gap Junctions of Neonatal Rat Hearts. European Journal of Physiology (1993) 423: 181-88.
• Chandrasekhar S, Munster PN, Henzel WA. and Daud AI. Purification and Characterization of a Novel 35 kilodalton protein from transformed cardiomyocytes. Cell Biol Int 23: 299-306, 1999.
• Zheng, F. F., Kuduk, S. D., Chiosis, G., Munster, P. N., Sepp-Lorenzino, L., Danishefsky, S. J., and Rosen, N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases, Cancer Res. 60: 2090-4, 2000.
• Munster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C. Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer. J Clin Oncol. 19 (7):2002-2009, 2001
• Munster PN, Srethapakdi M, Moasser M and Rosen N. Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells. Cancer Research 61: 2945-2952. 2001
• Chiosis, G, Lucas, B, Timaul, M, Munster PN and Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes HER2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 8(3):289-299, 2001
• Munster PN, Basso A, Solit D and Rosen N. Modulation of Hsp90 by Ansamycins sensitizes breast cancer cells to chemotherapy induced apoptosis in a schedule and RB dependent manner. Clin Cancer Research 2001, 7, 2228-2236
• Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA and Richon, VM. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells: Cancer Res. 2001 Dec 1;61(23):8492-7
• Basso A, Solit D, Munster PN and Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002 Feb 14;21(8):1159-66.
• Munster PN, Basso A, Solit D and Rosen N. Degradation of Her2 by ansamycins induces apoptosis and sensitizes HER2-overexpressing breast cancer cells to chemotherapy via a PI3K-AKT dependent pathway. Cancer Res 2002 Jun 1 (62) 3132-7.
• Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002 May;8(5):986-93.
• Munster PN, Marchion DC, Basso AD, Rosen N. Degradation HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'h-kinase-AKT-dependent pathway. Cancer Research 62, 3132-3137, June 1, 2002.
• Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15;21(6):1007-14
• Marchion, Douglas C., Bicaku, E, Daud, Adil I., Richon, Victoria, Sullivan, Daniel M., Munster PN. Potentiation of Topoisomerase II Inhibitor-induced DNA Damage by the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid. Journal of Cellular Biochemistry 92, 223-237, 2004.
• Daud AI, Valkov N, Centeno B, Derderian J, Sullivan P, Munster PN, Urbas P, DeConti R, Berghorn E, Liu Z, Hausheer E and Sullivan DM. Phase II trial of Karenitecin in Patients with Malignant Melanoma: A Clinical and Translational Study. Clin Cancer Res, April 2005;11(8):3009-16.
• Marchion DC, Bicaku E, Daud AI, Sullivan DM and Munster PN. Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins. Cancer Res, May 2005 65: (9):3815-22.
• Xu Q, Brabham JG, Zhang S, Munster PN, Fields K, Zhao RJ, Yu H. Chinese Herbal Formula, Bing De Ling, Enhances Antitumor Effects and Ameliorates Weight Loss Induced by 5-Fluorouracil in the Mouse CT26 Tumor Model.DNA Cell Biol. 2005 Jul;24(7):470-5.
• Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster PN, and Jacobsen PB. Cognitive Functioning after Adjuvant Chemotherapy and/or Radiotherapy for Early Stage Breast Carcinoma. Cancer 2005 Dec 1;104(11):2499-507.
• Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM and Munster PN. Synergistic interaction between HDAC and topo II inhibitors is mediated through topo IIbeta. Clin Cancer Res. 2005 Dec 1;11(23):8467-75.
• Marchion DC, Bicaku E, Daud AI, and Munster PN. In vivo synergy between topo II and HDAC inhibitors: Predictive correlates. Mol Cancer Ther. 2005 Dec;4(12):1993-2000.
• Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster PN, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM.. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol. 2006 Jul 1;24(19):3013-8.
• Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster PN, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan, DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 1;12(15):4645-51.
• Simon GR, Lush RM, Gump JL, Tetteh L, Williams C, Cantor A, Antonia S, Garrett S, Rocha-Lima C, Fishman M, Sullivan DM, and Munster PN. Sequential Oral 9-Nitrocamptothecin and Etoposide: A Pharmacodynamic and Pharmacokinetic Based Phase I Trial. Molecular Cancer Therapeutics. 2006 Aug;5(8):2130-7.
• Turner JG, Gump JL, Zhang C, Cook JM, Marchion DC, Hazlehurst L, Munster PN, Dalton WS and Sullivan DM. ABCG2 expression, function and promoter methylation in human multiple myeloma. Blood. 2006 Dec 1;108(12):3881-9.
• Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L and Tolcher AW. First Study of the Safety, Tolerability and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-expressing tumors. Clin Cancer Res. 2007 Feb 15;13(4):1238-45.
• Munster PN, Marchion D, Bicaku E, Schmitt M, Deconti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, and Daud A. Phase I trial of histone deacetylase inhibition by valproic acid (VPA) followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study. J Clin Oncol. 2007 May 20;25(15):1979-85.
• Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment. Health Psychol. 2007 Jul;26(4):464-72.
• Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemother Pharmacol. 2007 Sep 6; [Epub ahead of print].
• Jim H, Andykowski M., Munster PN, Jacobsen P, Physical Symptoms/Side Effects During Breast Cancer Treatment Predict Post-Treatment Distress. Annals of Behavioral Medicine 2007 Sep-Oct;34(2):200-8.
• Jacobsen P.B., Donovan K.A., Small B.J., Jim H.S., Munster PN, and Andrykowksi M.A. Fatigue following treatment for early stage breast cancer: A controlled comparison. Cancer 2007 Oct 15;110(8):1851-9.
• Homsi J, Simon GR, Garrett CR, Springett G, DeConti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM and Daud AI. Phase I trial of poly L-glutamate camtothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clinical Cancer Research, 2007 Oct 1;13(19):5855-61.
• Gwede C, Small B, Munster PN, Andrykowski M, Jacobsen P. Exploring the Differential Experience of Breast Cancer Treatment Related Symptoms. Journal of Supportive Care in Cancer. 2007 Nov 28; [Epub ahead of print]
• Bicaku E, Marchion DC, Schmitt ML, Munster PN. Selective inhibition of HDAC2 silences progesterone receptor mediated signaling. Cancer Research 2008 68: 1513-1519.
• Donovan KA, Jacobsen PB, Small BJ, Munster PN. Andrykowski MA. Identifying Clinically Meaningful Fatigue with the Fatigue Symptom Inventory. J Pain Symptom Manage. 2008 Nov; 36(5):480-7. Epub May 20.
• Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. Cancer. 2008 Nov 15;113(10):2646-54.
• Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. J Clin Oncol. 2008 Dec 20;26(36):5896-903. Epub 2008 Nov 24.